NEW YORK, August 4, 2016 /PRNewswire/ --
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
At the close on Wednesday, shares in Waltham, Massachusetts headquartered Tesaro Inc. saw a slight drop of 0.45%, ending the day at $95.17. The stock recorded a trading volume of 542,325 shares. The Company's shares have advanced 12.76% in the last one month, 137.57% over the previous three months, and 81.90% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 45.70% and 92.90%, respectively. Moreover, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally, have a Relative Strength Index (RSI) of 73.01.
On July 08th, 2016, European Network of Gynaecological Oncology Trial Groups announced that the Phase 3 ENGOT-OV16/NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival. This trial is led by Nordic Society of Gynaecological Oncology in partnership with TESARO, Inc. and is the first successful Phase 3 trial of a PARP inhibitor to be completed in ovarian cancer.
On July 19th, 2016, research firm Robert W. Baird initiated an 'Outperform' rating on the Company's stock, issuing a target price of $105 per share. The free research report on TSRO is available at:
Shares in Concord, California headquartered Cerus Corp. ended the day 0.28% lower at $7.17. A total volume of 2.67 million shares was traded, which was above their three months average volume of 1.18 million shares. In the last month and the previous three months, the stock has gained 14.35% and 22.98%, respectively. Additionally, the Company's shares have advanced 13.45% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 16.06% and 24.40%, respectively. Furthermore, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 69.08.
On July 07th, 2016, research firm Cantor Fitzgerald resumed its 'Buy' rating on the Company's stock, issuing a target price of $9 per share.
On July 21st, 2016, Cerus announced that its Q2 results will be released on August 4th, 2016, after the close of the stock market. The complimentary report on CERS can be downloaded at:
Five Prime Therapeutics
On Wednesday, shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. finished 2.38% higher at $51.68. A total volume of 805,370 shares was traded, which was above their three months average volume of 526,770 shares. The stock has advanced 20.47% in the last one month, 21.57% over the previous three months, and 24.53% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 17.42% and 31.59%, respectively. Additionally, shares of Five Prime Therapeutics, which focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes in the United States, have an RSI of 69.48.
On July 14th, 2016, Five Prime Therapeutics announced that GSK exercised its option to take an exclusive license to the intellectual property related to a target under the respiratory diseases research collaboration between the companies, triggering a $1.5 million license payment to Five Prime. Visit us today and download our complete research report on FPRX for free at:
New York headquartered Intercept Pharmaceuticals Inc.'s shares recorded a trading volume of 754,887 shares at the end of yesterday's session, which was higher than their three months average volume of 520,890 shares. The stock closed the day at $172.59, gaining 1.24%. The Company's shares have advanced 20.30% in the last one month, 24.05% in the previous three months, and 15.56% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.43% and 19.60%, respectively. Additionally, shares of Intercept Pharmaceuticals, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have an RSI at 64.24.
On July 06th, 2016, research firm Cantor Fitzgerald initiated a 'Sell' rating on the Company's stock, issuing a target price of $58 per share.
On July 28th, 2016, Intercept Pharmaceuticals announced that it will report its Q2 2016 financial results prior to the NASDAQ market open on August 4th, 2016. Get free access to your technical report on ICPT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA